Beyond the Label: FDA Addresses Permissible Scope of Communications With Payors and Physicians

by Pepper Hamilton LLP
Contact

The draft guidances create a grey area between “on-label” and “off-label” communications that will require careful navigation as manufacturers develop HCEI analyses and promotional communications.

In two recent draft guidances and a memorandum, the Food and Drug Administration (FDA) acknowledges a public health need for certain information outside the four corners of FDA-approved product labeling, signaling a new flexibility with respect to company communications with health care providers and payors. At the same time, the agency repeats its position that “off-label” communications remain unacceptable.

One draft guidance covers manufacturers’ communication of health care economic information (HCEI) — analysis of the “value” of a medical treatment (i.e., cost, efficacy, efficiency, etc.) — to payors, formulary committees and similar entities, as well as pre-approval communications with payors about investigational products.1 The other addresses manufacturers’ communications to health care providers that the FDA considers consistent with approved product labeling.2 The memorandum states the FDA’s position on First Amendment considerations related to “off-label” communications about unapproved uses of a product — a hotly debated issue between the FDA and industry.3 Together, these new statements provide a basis for both optimism and caution. While the FDA will accept the communication of some truthful and nonmisleading information that is outside the label, grey areas between permissible and impermissible communications remain.

Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities

This draft guidance clarifies that the FDA does not consider HCEI that “directly relates to an approved indication and is based on competent and reliable scientific evidence” to be false or misleading when accompanied by a “conspicuous and prominent statement describing any material differences” between the HCEI and the approved labeling. To be considered “related to an approved indication, HCEI analyses should relate to the disease or condition, manifestation of the disease or condition, or symptoms associated with the disease or condition in the patient population” for which the drug is approved. HCEI analyses may be considered “related” even if they incorporate information that does not appear within, and may vary from, information presented in the FDA-approved labeling.

The draft guidance provides several examples of analyses “related to” an FDA-approved indication that may be shared with payors. These include:

  • Validated Surrogate Endpoints — HCEI analyses may be derived from clinical data demonstrating an effect on a surrogate endpoint that is known to predict clinical benefit (e.g., blood pressure reduction as a validated surrogate endpoint for reduction in certain cardiovascular events pertaining to antihypertensive drugs).

  • Patient Subgroups — HCEI analyses may be derived from analyses of treatment effects in patient subgroups that are within the patient population for the approved indication, even if these subgroup analyses were not pre-specified in the approval studies.

  • Comparisons — HCEI analyses may be derived from studies comparing the safety or effectiveness of a drug for its approved indication to another drug or to no treatment.

HCEI analyses must be based on competent and reliable scientific evidence (CARSE). The FDA will consider an analysis to be based on CARSE if it has been developed using generally accepted scientific standards, appropriate for the information being conveyed, that yield accurate and reliable results. The draft guidance also describes the types of information that manufacturers should include when providing HCEI to payors, such as the limitations of the economic analyses, a statement describing the material differences from the FDA-approved labeling, omitted data sources or studies (including the results of a comprehensive literature search and an explanation of the methods used to determine which data to include or exclude), and any additional risk information related to variations from the FDA-approved labeling.

This draft guidance also permits companies to provide payors with certain kinds of information about unapproved investigational products, recognizing that payors may need some information ahead of approval for coverage and reimbursement planning. The FDA does not intend to object under the regulations prohibiting the promotion of investigational drugs and devices — provided (1) the information is “unbiased, factual, accurate, and non-misleading” and (2) the communication includes a clear statement that the product is investigational and that the safety or effectiveness of the product has not been established, together with information about the stage of product development. The guidance lists the kinds of information that can be communicated. This includes such information about the product as its class and design, the indications sought, and “factual presentations” of study results, with no characterizations or conclusions about the safety or effectiveness of the product.

Medical Product Communications That Are Consistent With the FDA-Required Labeling

This second draft guidance explains how the FDA evaluates medical product communications, including promotional materials, that include information not contained in the FDA-required labeling, but that may be consistent with the labeling. Information that is “consistent with” the labeling is limited to information about the approved or cleared uses of a product. All such information must be conveyed in a truthful, nonmisleading way. The FDA states that, if any representations are false and misleading, the communication would misbrand the product, regardless of whether it is consistent with the labeling. For example, pivotal study data showing an individual component of a composite primary endpoint should not be used to claim efficacy for the component if that analysis was not sufficiently powered.

The FDA describes three factors that it will consider in determining whether a communication is consistent with the FDA-required labeling.

  • Factor 1: How the information in the communication compares to the information about the conditions of use in the FDA-required labeling including:

    • Whether the representations relate to a different indication than those in the FDA-approved labeling

    • Whether the representations are outside the approved/cleared patient population in the FDA-approved labeling

    • Whether the representations conflict with the limitations or directions for handling, preparing or using the product in the FDA-approved labeling

    • Whether the representations conflict with the recommended dosage or use regimen, route of administration or strengths set forth in the FDA-required label.

  • Factor 2: Whether the representations in the communication increase the potential for harm relative to the information reflected in the FDA-required labeling.

  • Factor 3: Whether the directions for use in the FDA-required labeling enable the product to be safely and effectively used under the conditions represented or suggested in the communication.

The agency also provides several examples of information that would be “consistent with” the FDA-approved label. Some of these examples may expand the current boundaries on promotional communications. For example:

  • Information based on a comparison of the safety or efficacy of a medical product for its approved/cleared indication to another medical product approved/cleared for the same indication (e.g., a firm’s communication provides information from a head-to-head study indicating that its drug that is approved to treat high blood pressure in adults has superior efficacy to another drug that is also approved to treat high blood pressure in adults)

  • Information about the onset of action of the product for its approved/cleared indication and dosing/use regimen

  • Information that provides additional context about the mechanism of action described in the FDA-required labeling.

To be truthful and not misleading, communications “need to be grounded in fact and science and presented with appropriate context.” The evidentiary support should be “scientifically appropriate and statistically sound to support the representations or suggestions made in the communication.” To avoid a presentation that is false and misleading, the FDA recommends “accurately characterizing and contextualizing the relevant information, including by disclosing unfavorable or inconsistent findings” and providing any data or information from the FDA-required labeling that relates to what is represented in the communication.

Memorandum: Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products

In November 2016, the FDA held a public hearing to obtain input on issues related to communications regarding unapproved uses of approved or cleared medical products. The FDA’s recent memorandum provides additional background on the issues it is considering as it reviews its rules and policies on “off-label” communications, including First Amendment considerations. The FDA acknowledges that its current policies on communications about unapproved product uses implicate its interest in advancing the public health, including the development of robust safety and efficacy data; protecting against fraud, misrepresentation and bias; and protecting the integrity and reliability of promotional materials. The agency notes that the risk of adverse events is higher for unapproved uses and offers examples of cases where false and misleading marketing has caused patient harm.

Here, the FDA recognizes that companies’ communications regarding unapproved uses may advance public health by supporting informed decision-making for patient treatment and furthering scientific understanding and research. The agency also discusses the tension between its policies and First Amendment considerations, highlighting some of the merits of alternative approaches to harmonizing the competing interests implicated by these communications. While the memorandum outlines the circumstances where the FDA’s current approach permits discussion regarding “off-label” use (such as continuing medical education programs and presentations at scientific conferences) and describes the relevant First Amendment jurisprudence, it does not provide clarity on the policies the FDA intends to adopt.

Potential Implications for Drug and Device Manufacturers

Giving payors and physicians access to information that is “related to” or “consistent with” the FDA-approved label, but outside its four corners, serves the public interest, impacting both product accessibility and individual patient care. However, the draft guidances create a grey area between “on-label” and “off-label” communications that will require careful navigation as manufacturers develop HCEI analyses and promotional communications. For example:

  • As both draft guidances emphasize, whether a communication is false and misleading will be a fact-specific determination.

  • The FDA’s examples of permissible communications relate to areas that have traditionally been the subject of FDA enforcement actions, including comparative claims, use of validated surrogate endpoints in communications with payors, and claims related to a product’s mechanism of action.

  • The standards for the types of evidence that may support the communications are subjective.

While the FDA has not detailed the circumstances in which it will take enforcement action, it suggests that it will focus on the quality of the evidence supporting a company’s communications, whether the company addresses unfavorable or inconsistent findings, and whether the communication adequately describes material differences from the FDA-required labeling. Manufacturers should also consider what standard-setting role these draft guidances may play beyond FDA regulation — particularly in state government and private litigation, where plaintiffs are challenging marketing communications under state consumer protection statutes, the Lanham Act, and other advertising laws or in product liability claims.

Will the FDA continue to broaden the types of truthful, nonmisleading information that may be shared with payors and physicians? Or do these draft guidances and memorandum represent the outer limits of what information manufacturers may share beyond the FDA-approved label? As the FDA continues to refine its policies in this area, drug and device manufacturers should proceed cautiously in conveying scientifically appropriate information that is “related to” or “consistent with” the FDA-approved labeling to payors and health care providers.

The FDA has opened the comment period for these three documents for 90 days, until April 19, 2017.

 

 

 

Endnotes

1 Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities – Questions and Answers (Jan. 2017), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM537347.pdf
.

2 Medical Product Communications That Are Consistent With the FDA-Required Labeling – Questions and Answers (Jan. 2017), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM537130.pdf
.

3 FDA Memorandum: Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products (Jan. 2017), available at https://www.federalregister.gov/documents/2017/01/19/2017-01013/manufacturer-communications-regarding-unapproved-uses-of-approved-or-cleared-medical-products.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pepper Hamilton LLP | Attorney Advertising

Written by:

Pepper Hamilton LLP
Contact
more
less

Pepper Hamilton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.